Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
clinical trials
eligibility
exclusion criteria
inclusion criteria
primary brain tumor
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
pubmed:
25
1
2020
medline:
28
4
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
Building on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
Identifiants
pubmed: 31974566
pii: 5715205
doi: 10.1093/neuonc/noaa015
pmc: PMC7229255
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-612Subventions
Organisme : NCI NIH HHS
ID : U01 CA137443
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA137443
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Oncotarget. 2017 Dec 14;8(69):114268-114280
pubmed: 29371985
Clin Neuropathol. 2018 Mar/Apr;37 (2018)(2):53-63
pubmed: 29393845
J Clin Oncol. 2017 Nov 20;35(33):3737-3744
pubmed: 28968170
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Lancet Oncol. 2013 Aug;14(9):823-33
pubmed: 23850491
J Immunother Cancer. 2018 Aug 31;6(1):84
pubmed: 30170629
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Neuro Oncol. 2009 Oct;11(5):550-5
pubmed: 19332770
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Cancer Invest. 2013 Feb;31(2):140-4
pubmed: 23362951
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
J Neurooncol. 2018 Apr;137(2):409-415
pubmed: 29294233
Neurology. 2017 Sep 12;89(11):1152-1161
pubmed: 28814455
Ann Oncol. 2018 Mar 1;29(3):766-771
pubmed: 29351570
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
J Clin Oncol. 2011 Aug 20;29(24):3211-3
pubmed: 21768451
Neuro Oncol. 2019 Jun 07;:
pubmed: 31175826
J Clin Oncol. 2017 Nov 20;35(33):3774-3780
pubmed: 28968173
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Neuro Oncol. 2017 Oct 1;19(10):1327-1337
pubmed: 28575485
Eur J Cancer. 2017 Oct;84:202-211
pubmed: 28826073
Acta Neuropathol. 2018 Nov;136(5):793-803
pubmed: 30187121
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
J Clin Oncol. 2020 Jan 1;38(1):81-99
pubmed: 31743054
J Clin Oncol. 2017 Nov 20;35(33):3760-3773
pubmed: 28968165
Neuro Oncol. 2018 Jan 10;20(1):66-77
pubmed: 29016839
Orphanet J Rare Dis. 2019 Feb 7;14(1):31
pubmed: 30732630
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
J Immunother Cancer. 2018 Jun 11;6(1):51
pubmed: 29891009
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
pubmed: 19755387
CNS Oncol. 2017 Oct;6(4):307-313
pubmed: 28990795
Am J Clin Oncol. 2018 Feb;41(2):191-196
pubmed: 28832384
Acta Neuropathol. 2017 Dec;134(6):957-959
pubmed: 29052002
J Clin Oncol. 2015 Oct 1;33(28):3186-92
pubmed: 26282642
Oncologist. 2018 Oct;23(10):1242-1249
pubmed: 29700209
J Clin Oncol. 2017 Nov 20;35(33):3753-3759
pubmed: 28968172
J Neurooncol. 2017 Jun;133(2):309-313
pubmed: 28560660
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
J Natl Cancer Inst. 2014 Sep 12;106(10):
pubmed: 25217580
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
J Clin Oncol. 2017 Nov 20;35(33):3781-3787
pubmed: 28968169
J Clin Oncol. 2004 May 1;22(9):1583-8
pubmed: 15051755
Acta Neuropathol. 2015 May;129(5):679-93
pubmed: 25783747
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuro Oncol. 2016 Sep;18(9):1191-2
pubmed: 27530501
Neuro Oncol. 2018 Jul 5;20(8):1034-1043
pubmed: 29518210